Fruquintinib provides improvement in overall survival for refractory mCRC
Fruquintinib provides improvement in overall survival for refractory mCRC
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO
A new era of early cancer detection with blood test may change cancer screening paradigms
New era of early cancer detection blood tests on the horizon
Hyperthermic intraperitoneal chemo for locally advanced colon cancer
Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19
New data presented at ESMO for multi-cancer early detection
OncoAlert and ecancer weekly round up for August 15th - 21st, 2022
An overview of treatment advances in gastric cancer
Optimum treatment strategy algorithm for mCRC
MOUNTAINEER: Tucatinib in combination with trastuzumab for HER2-positive mCRC
Working to improve global cancer care access in low middle-income countries